6月19日，Kardigan盘中上涨42.28%，报22.765美元/股，成交额9976.32万美元。
消息面上，Kardigan于当日正式登陆纳斯达克市场，以每股16美元的价格发行2500万股，募资约4亿美元，定价位于此前14至16美元发行区间上限，并授予承销商30天内超额配售375万股的选择权。首日交易中股价最高触及21美元上方，市场追捧情绪显著。
Kardigan是一家临床阶段精准心血管疗法公司，旗下拥有Danicamtiv、Ataciguat及Tonlamarsen三项后期临床管线，均聚焦当前尚无获批疗法的心血管适应症。公司核心管理团队源自MyoKardia体系，并依托Prolaio人工智能平台加速药物研发。公司目前尚无商业化收入，最近一个财年净亏损约1.92亿美元。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.